AngioDynamics (NASDAQ:ANGO) Shares Up 11.2% on Earnings Beat

AngioDynamics, Inc. (NASDAQ:ANGO) shares traded up 11.2% during trading on Wednesday following a better than expected earnings announcement. The stock traded as high as $14.56 and last traded at $14.4550. Approximately 180,008 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 471,780 shares. The stock had previously closed at $13.00.

The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 10.01% and a negative return on equity of 4.66%. The firm had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

AngioDynamics News Summary

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported quarterly EPS of -$0.07, beating estimates of -$0.11, while revenue of $86.61 million topped forecasts of $80.24 million. AngioDynamics earnings report
• Positive Sentiment: The company said it delivered record fourth-quarter and full-year results, with continued execution driving med-tech growth and full-year profitability, reinforcing the turnaround narrative. Business Wire release
• Positive Sentiment: Management raised FY2027 revenue guidance to $336 million–$341 million, above consensus, signaling confidence in future demand and execution. MSN summary article
• Neutral Sentiment: Despite the beat, the company still posted a quarterly loss and has negative margins, so investors may remain focused on whether revenue growth can continue to translate into sustained profitability.
• Negative Sentiment: FY2027 EPS guidance of -$0.29 to -$0.24 was weaker than analysts expected, which could limit upside if investors prioritize profit outlook over sales growth.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ANGO. Zacks Research cut AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Monday, April 20th. Freedom Capital raised shares of AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Finally, Canaccord Genuity Group set a $20.00 price objective on shares of AngioDynamics in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, AngioDynamics currently has an average rating of “Moderate Buy” and an average price target of $20.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ANGO. D.A. Davidson & CO. bought a new stake in shares of AngioDynamics in the fourth quarter worth approximately $1,751,000. Weber Capital Management LLC ADV bought a new position in AngioDynamics during the fourth quarter valued at approximately $17,978,000. Armistice Capital LLC lifted its position in AngioDynamics by 3.9% during the fourth quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock valued at $21,828,000 after purchasing an additional 64,000 shares during the period. Royce & Associates LP boosted its holdings in AngioDynamics by 27.3% in the fourth quarter. Royce & Associates LP now owns 1,267,451 shares of the medical instruments supplier’s stock worth $16,274,000 after purchasing an additional 272,091 shares during the last quarter. Finally, Acuitas Investments LLC boosted its holdings in AngioDynamics by 12.7% in the third quarter. Acuitas Investments LLC now owns 498,530 shares of the medical instruments supplier’s stock worth $5,569,000 after purchasing an additional 56,300 shares during the last quarter. 89.43% of the stock is owned by institutional investors.

AngioDynamics Stock Performance

The firm has a market cap of $594.22 million, a P/E ratio of -19.24 and a beta of 0.34. The business’s 50-day simple moving average is $12.07 and its 200 day simple moving average is $11.32.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.